"Most clinical conditions we see in day-to-day practice are influenced by the microbiome, and so many of our gastrointestinal therapies conversely lead to changes in the microbiome. We are at the forefront of understanding these important interactions." - Dr. Leo Treyzon, MD
SAN FRANCISCO (PRWEB) October 04, 2018
uBiome, the leader in microbial genomics, announces the addition of Leo Treyzon, MD, Attending Gastroenterologist, Division of Gastroenterology at Cedars-Sinai Medical Center, to its Medical Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Treyzon will bring to uBiome his extensive experience in gastrointestinal conditions including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastritis (H. Pylori), as well as various cancers of the digestive tract. This appointment will aid uBiome’s continuous advancement in human microbiome research.
“The majority of the human microbiome is found in the gut, and Dr. Treyzon has spent his career focusing on gastrointestinal conditions that are associated with bacteria and other microorganism imbalances,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are absolutely delighted to bring his expertise to uBiome’s Medical Advisory Board.”
For over 10 years, Dr. Treyzon’s clinical practice has been based at Cedars-Sinai Medical Center, and he has become one of the foremost leaders in private practice gastroenterology in the greater Los Angeles area. In 2012, Dr. Treyzon became the only gastroenterology doctor in the Los Angeles area to become a certified Diplomate of the American Board of Obesity Medicine. He is a participating physician and researcher in the Cedars-Sinai Weight Loss Center, Esophageal Center, and Cancer Center. Dr. Treyzon also serves as assistant professor at the David Geffen School of Medicine at the University of California Los Angeles (UCLA).
About joining uBiome's Medical Advisory Board, Dr. Treyzon said, "Our awareness of the relationship between the the human host and the microbiome is of escalating importance. This knowledge base has made a huge impact in our ability to manage complex conditions such as irritable bowel syndrome. Most clinical conditions we see in day-to-day practice are influenced by the microbiome, and so many of our gastrointestinal therapies conversely lead to changes in the microbiome. We are at the forefront of understanding these important interactions."
In addition to Dr. Treyzon, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Greene (Society for Participatory Medicine), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutics.
uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.ubiome.com